RP-32261

RP-32261 is a small molecule inhibitor of the Ras-related C3 botulinum toxin substrate 1 (Rac1) GTPase, currently under development by Revere Pharmaceuticals. Rac1 is a member of the Rho family of GTPases and serves as a critical regulator of the actin cytoskeleton, influencing cellular processes such as migration, adhesion, and cell cycle progression. Overactivation or dysregulation of Rac1 signaling is frequently implicated in the progression, metastasis, and therapeutic resistance of various malignancies. RP-32261 is currently in the IND-enabling phase of development. While specific indications for this particular code name are not explicitly detailed in company pipeline summaries, Revere's broader Rac1-targeting platform is focused on solid tumors, including colorectal cancer and non-small cell lung cancer.